CVS Pharmacy has reached a $315 million settlement with the U.S. Department of Justice (DOJ) to resolve allegations that the company illegally filled prescriptions for opioids and other controlled substances, and subsequently sought reimbursement from Medicare and other federal health care programs for many of these prescriptions [1]. The DOJ's case, brought in 2024, alleged that CVS knowingly filled prescriptions lacking a legitimate medical purpose or issued outside the usual course of professional practice, covering prescriptions filled between October 2013 and December 2025 [1].
According to the DOJ, CVS pharmacists allegedly filled prescriptions involving excessive quantities of opioids, early refills, and dangerous drug combinations such as the 'trinity'—a combination of an opioid, a benzodiazepine, and a muscle relaxant [1]. The DOJ further claimed that CVS filled prescriptions from 'pill mill' prescribers and ignored warning signs or 'red flags' indicating a high probability of illegitimacy, with many of these prescriptions ultimately billed to and reimbursed by federal health care programs [1]. The DOJ also alleged that CVS' corporate performance metrics, incentive compensation, and staffing policies prioritized profits over patient safety, contributing to the violations [1].
As part of the settlement, CVS did not admit wrongdoing and disputed the government's allegations, stating that its more than 27,000 pharmacists are highly trained in the safe and appropriate use of all medications [1]. In addition to the financial penalty, CVS entered into an agreement with the Drug Enforcement Administration (DEA) to implement additional safeguards, including establishing a hotline for reporting suspected illegal dispensing, proactively monitoring dispensing patterns, and evaluating prescribers suspected of illegal activity [1].
This settlement follows a previous agreement in 2022, in which CVS agreed to pay nearly $5 billion to settle thousands of opioid-related claims brought by state, local, and tribal governments [1]. DOJ officials described the current settlement as a significant milestone in efforts to combat the opioid epidemic and hold pharmacies accountable for unlawful dispensing practices [1].
CONCLUSION
The $315 million settlement marks a major development in the federal government's efforts to address the opioid crisis by targeting pharmacy practices. While CVS did not admit wrongdoing, the agreement imposes new compliance measures and financial penalties. The outcome signals heightened regulatory scrutiny and potential financial and reputational impacts for CVS.